Want to see IONS full AI Analyst Report?
Ionis Pharmaceuticals (IONS) Stock Statistics & Valuation Metrics
Total Valuation
Ionis Pharmaceuticals has a market cap or net worth of $7.23B. The enterprise value is $13.25B.
- Market Cap
- $7.23B
- Enterprise Value
- $13.25B
Share Statistics
Ionis Pharmaceuticals has 166,184,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 166,184,330
- Owned by Insiders
- 0.78%
- Owned by Institutions
- 63.97%
Financial Efficiency
Ionis Pharmaceuticals’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -11.96%.
- Return on Equity (ROE)
- -0.78
- Return on Assets (ROA)
- -0.11
- Return on Invested Capital (ROIC)
- -11.96%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 637.84K
- Profits Per Employee
- -257.43K
- Employee Count
- 1,480
- Asset Turnover
- 0.27
- Inventory Turnover
- 1.59
Valuation Ratios
The current PE Ratio of Ionis Pharmaceuticals is -12.58. Ionis Pharmaceuticals’s PEG ratio is 0.15.
- PE Ratio
- -12.58
- PS Ratio
- 8.28
- PB Ratio
- 16.37
- Price to FCF
- -12.94
- Price to Operating Cash Flow
- -14.50
- PEG Ratio
- 0.15
Income Statement
In the last 12 months, Ionis Pharmaceuticals had revenue of 944.00M and earned -381.00M in profits. Earnings per share was -2.38.
- Revenue
- 944.00M
- Gross Profit
- 928.00M
- Operating Income
- -382.00M
- Pretax Income
- -380.00M
- Net Income
- -381.00M
- EBITDA
- -284.31M
- Earnings Per Share (EPS)
- -2.38
Cash Flow
In the last 12 months, operating cash flow was -496.43M and capital expenditures -62.44M, giving a free cash flow of -558.88M billion.
- Operating Cash Flow
- -496.43M
- Free Cash Flow
- -558.88M
- Free Cash Flow per Share
- -3.38
Dividends & Yields
Ionis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.73%
- Earnings Yield
- -7.85%
Stock Price Statistics
- Beta
- 0.93
- 52-Week Price Change
- -41.32%
- 50-Day Moving Average
- 48.99
- 200-Day Moving Average
- 66.71
- Relative Strength Index (RSI)
- 43.14
- Average Volume (3m)
- 3.14M
Important Dates
Ionis Pharmaceuticals upcoming earnings date is Nov 04, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jul 29, 2026
- Next Earnings Date
- Nov 04, 2026
- Ex-Dividend Date
- ―
Financial Position
Ionis Pharmaceuticals as a current ratio of 3.83, with Debt / Equity ratio of 534.53%
- Current Ratio
- 3.83
- Quick Ratio
- 3.81
- Debt to Market Cap
- 0.19
- Net Debt to EBITDA
- -7.89
- Interest Coverage Ratio
- -4.22
Taxes
In the past 12 months, Ionis Pharmaceuticals has paid 1.00M in taxes.
- Income Tax
- 1.00M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Ionis Pharmaceuticals EV to EBITDA ratio is -19.38, with an EV/FCF ratio of -16.64.
- EV to Sales
- 10.64
- EV to EBITDA
- -19.38
- EV to Free Cash Flow
- -16.64
- EV to Operating Cash Flow
- -18.74
Balance Sheet
Ionis Pharmaceuticals has $2.05B in cash and marketable securities with $2.42B in debt, giving a net cash position of -$363.89M billion.
- Cash & Marketable Securities
- $2.05B
- Total Debt
- $2.42B
- Net Cash
- -$363.89M
- Net Cash Per Share
- -$2.19
- Tangible Book Value Per Share
- $2.65
Margins
Gross margin is 98.16%, with operating margin of -68.09%, and net profit margin of -64.64%.
- Gross Margin
- 98.16%
- Operating Margin
- -68.09%
- Pretax Margin
- -64.33%
- Net Profit Margin
- -64.64%
- EBITDA Margin
- -54.92%
- EBIT Margin
- -57.44%
Analyst Forecast
The average price target for Ionis Pharmaceuticals is $84.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $84.78
- Price Target Upside
- 94.80% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 19
- Revenue Growth Forecast
- -7.49%
- EPS Growth Forecast
- -98.12%
Scores
- Smart Score
- 8
- AI Score
- 48
